Taro Pharmaceutical Industries (NYSE:TARO) released its quarterly earnings data on Monday, November 4th. The company reported $1.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.72 by ($0.26), Fidelity Earnings reports. Taro Pharmaceutical Industries had a net margin of 40.43% and a return on equity of 14.13%. The business had revenue of $160.85 million during the quarter, compared to analyst estimates of $168.60 million.
TARO traded up $1.00 during trading on Wednesday, hitting $95.62. The stock had a trading volume of 75,564 shares, compared to its average volume of 66,725. The firm has a market cap of $3.51 billion, a PE ratio of 13.23 and a beta of 0.43. Taro Pharmaceutical Industries has a 12 month low of $72.97 and a 12 month high of $109.42. The company has a 50 day simple moving average of $80.88 and a 200-day simple moving average of $84.03.
Several equities research analysts recently issued reports on TARO shares. ValuEngine raised shares of Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective (up previously from $105.00) on shares of Taro Pharmaceutical Industries in a research note on Tuesday, November 5th. Finally, Zacks Investment Research lowered shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research note on Friday, November 8th.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Receive News & Ratings for Taro Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.